Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Investigating Mechanisms Behind Immunological Mystery

By Northwestern Medicine | August 10, 2016

Northwestern Medicine scientists have identified a new potential target for treating autoimmune diseases in recent research published in Nature Communications.

Autoimmune diseases such as multiple sclerosis and lupus, which affect more than 23 million Americans, occur when white blood cells in the immune system called T-cells fail to distinguish between the self and foreign antigens, causing the T-cells to attack healthy cells. The mechanisms underlying this impaired “T-cell tolerance” are still a mystery to scientists.

“The current dogma is that receptors on self-reactive T-cells promote the expression of genes known as anergic genes, which suppress the activation of those T-cells,” said principal investigator Deyu Fang, PhD, professor of Pathology. “Based on this theory, during the last decade immunologists including those in my laboratory have identified several signaling suppressors induced by self-antigens, which are critical for T-cell immune tolerance induction.”

Fang’s team suggests that certain signaling increases the genes that suppress self-attacking T-cells and others decrease the activators that maintain T-cell tolerance, “similar to a vehicle that can be slowed down by either tightening a break or shutting off the gas pedal,” he explained.

In the new study, scientists compared the gene expression profiles of anergic T-cells and showed that decreasing expression of the protein Hrd1 leads to T-cell tolerance.

“We then generated T-cell-specific Hrd1 knockout mice and demonstrated that genetic deletion of the Hrd1 gene promotes T-cell tolerance induction: It inhibits T-cell activation and protects mice from autoimmune disease,” Fang said. “More importantly, we discovered that Hrd1 expression is increased in T-cells from patients with multiple sclerosis and Hrd1 suppression weakened human T-cell activation.”

In a previous paper published in the Journal of Experimental Medicine, Fang’s group showed that Hrd1 is required by dendritic cells, messengers that present antigens to T-cells. Genetically suppressing Hrd1 protected mice from autoimmune disease. In another forthcoming paper, the scientists showed that the same protein plays a critical role for B-cells, white blood cells that produce antibodies.

“Based on the recent discoveries in our laboratory, we believe that Hrd1 is a potential therapeutic target for autoimmune diseases, as its suppression inhibits the functions of T-cells, B-cells and dendritic cells,” Fang said.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE